{"brief_title": "Study Evaluating ReFacto AF in Severe Hemophilia A", "brief_summary": "To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity.", "condition": "Hemophilia A", "intervention_type": "Drug", "intervention_name": "ReFacto AF", "criteria": "Inclusion Criteria: - Severe hemophilia A (FVIII:C less than or equal to 2% at local laboratory) - Previously treated patients with greater than or equal to 250 exposure days to any Factor VIII product - Age greater than or equal to 12 years - History of prophylaxis dosing at least twice per week on any Factor VIII product for at least 3 consecutive months within the 2 years prior to study enrollment unless the patient completed the previous pharmacokinetic study - Adequate laboratory results Exclusion Criteria: - Presence of any bleeding disorder in addition to hemophilia A - Concomitant therapy with immunosuppressive drugs - Current or historical Factor VIII inhibitor - Treatment with any investigational drug or device within the past 30 days", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00037544.xml"}